Vimian Group (VIMIAN) Stock Overview
Engages in the animal health business worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
VIMIAN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Vimian Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 29.25 |
| 52 Week High | SEK 43.58 |
| 52 Week Low | SEK 24.18 |
| Beta | 1.17 |
| 1 Month Change | 4.65% |
| 3 Month Change | 1.99% |
| 1 Year Change | -28.69% |
| 3 Year Change | 11.13% |
| 5 Year Change | -72.92% |
| Change since IPO | -63.84% |
Recent News & Updates
Narrative Update • Jun 30
VIMIAN: Lower Margin Outlook Will Limit Future Share Price Upside
Analysts have lifted their SEK fair value estimate for Vimian Group from about SEK 24.91 to roughly SEK 26.50. They cited updated assumptions for revenue growth, profit margins and a higher future P/E multiple as key drivers behind the change in price target.
Narrative Update • Jun 16
VIMIAN: Lower Discount Rate And New Bylaws Will Support Future Repricing
Analysts have kept their SEK price target for Vimian Group broadly in line with prior estimates, citing slightly adjusted assumptions around the company’s discount rate, revenue growth, profit margin and future P/E as the main drivers of the updated view. What's in the News Vimian Group AB held its Annual General Meeting on April 29, 2026, where shareholders approved the adoption of new Articles of Association.Narrative Update • Jun 01
VIMIAN: New Bylaws And Improved Assumptions Will Support Future Repricing
Analysts now set their fair value price target for Vimian Group at SEK41.03, a slight trim from SEK41.10. This reflects updated views on discount rates, revenue growth, profit margins, and future P/E assumptions.
Narrative Update • May 06
VIMIAN: Margin Execution And Governance Changes Will Support Future Upside Potential
Analysts now see fair value for Vimian Group at about SEK 35, up from roughly SEK 34, even though the latest Street research includes a reduced price target to SEK 25 from SEK 27. This reflects updated views on revenue growth, margins, the appropriate discount rate and future P/E assumptions.Recent updates
Narrative Update • Jun 30
VIMIAN: Lower Margin Outlook Will Limit Future Share Price Upside
Analysts have lifted their SEK fair value estimate for Vimian Group from about SEK 24.91 to roughly SEK 26.50. They cited updated assumptions for revenue growth, profit margins and a higher future P/E multiple as key drivers behind the change in price target.Narrative Update • Jun 16
VIMIAN: Lower Discount Rate And New Bylaws Will Support Future Repricing
Analysts have kept their SEK price target for Vimian Group broadly in line with prior estimates, citing slightly adjusted assumptions around the company’s discount rate, revenue growth, profit margin and future P/E as the main drivers of the updated view. What's in the News Vimian Group AB held its Annual General Meeting on April 29, 2026, where shareholders approved the adoption of new Articles of Association.Narrative Update • Jun 01
VIMIAN: New Bylaws And Improved Assumptions Will Support Future Repricing
Analysts now set their fair value price target for Vimian Group at SEK41.03, a slight trim from SEK41.10. This reflects updated views on discount rates, revenue growth, profit margins, and future P/E assumptions.Narrative Update • May 06
VIMIAN: Margin Execution And Governance Changes Will Support Future Upside Potential
Analysts now see fair value for Vimian Group at about SEK 35, up from roughly SEK 34, even though the latest Street research includes a reduced price target to SEK 25 from SEK 27. This reflects updated views on revenue growth, margins, the appropriate discount rate and future P/E assumptions.Narrative Update • Apr 17
VIMIAN: Higher Discount Rate Will Constrain Future Upside Potential
Analysts have trimmed their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated views on discount rates, growth and profitability assumptions. Analyst Commentary Bearish analysts are signaling a more cautious stance on Vimian Group, with the latest move being a reduction in the price target to SEK 25 from SEK 27.Narrative Update • Apr 03
VIMIAN: Margin Execution And New Bylaws Will Support Future Upside Potential
Analysts have reduced their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on margins and valuation multiples that result in a slightly adjusted fair value model. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with the updated SEK 25 price target reflecting revised assumptions on margins and valuation multiples rather than a shift in rating.Narrative Update • Mar 20
VIMIAN: Lower Price Outlook And Execution Risks Will Shape Fair Value Balance
Analysts have trimmed their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on growth, margins and valuation multiples that align the target more closely with recent research views. Analyst Commentary Recent research reflects a cautious tone around Vimian Group, with the latest move being a trim in the price target to SEK 25 from SEK 27.Narrative Update • Mar 05
VIMIAN: Reduced Price Outlook And Execution Risks Will Shape Fairly Balanced Prospects
Analysts have lowered their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts have trimmed their fair value assumptions for Vimian Group, as seen in the reduced price target to SEK 25 from SEK 27.Narrative Update • Feb 19
VIMIAN: Reset Expectations Will Highlight Execution Under New CEO Appointment
Analysts have trimmed their fair value estimate and price target on Vimian Group to SEK 27 from SEK 37, reflecting updated assumptions around slightly higher growth, a lower profit margin profile and a higher expected P/E multiple, which together point to a more cautious risk return trade off. Analyst Commentary Bullish analysts looking at Vimian Group are focusing less on the headline downgrade and more on what the revised SEK 27 target implies for execution, valuation and growth expectations from here.Analysis Article • Feb 16
Vimian Group AB (publ) (STO:VIMIAN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Investors in Vimian Group AB (publ) ( STO:VIMIAN ) had a good week, as its shares rose 5.9% to close at kr27.84...Analysis Article • Feb 05
Is Vimian Group (STO:VIMIAN) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narrative Update • Feb 05
VIMIAN: Future Leadership Change Will Support Execution Upside Despite Sector Downgrade
Narrative update Analysts have trimmed their price expectations for Vimian Group, with the updated fair value estimate easing from SEK 36.92 to SEK 33.76, as some now see lower future P/E assumptions and have adopted more cautious views similar to the recent SEK 27 price target cut in Street research. Analyst Commentary Recent research updates on Vimian Group have taken a more cautious tone, with the shift to an Underweight rating and a price target of SEK 27, down from SEK 37.Narrative Update • Jan 22
VIMIAN: Rebased Expectations Will Spotlight Execution Under New Leadership Transition Narrative
Analysts have reduced their fair value estimate for Vimian Group to SEK 41.36 from SEK 41.97, citing slightly higher discount rate assumptions and updated sector views. This follows a recent cut in the Street price target to SEK 27 from SEK 37.Narrative Update • Jan 08
VIMIAN: Rebased Expectations Will Highlight Execution On M&A-Led Expansion Narrative
Analysts have lowered their fair value estimate for Vimian Group from SEK 51.65 to SEK 41.97, citing more cautious assumptions on revenue growth and valuation multiples in line with recent price target cuts, including the move to SEK 27 from SEK 37 in Barclays' 2026 industry outlook. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with fair value and price targets recalibrated to reflect updated assumptions on revenue growth and sector valuation.Analysis Article • Jan 08
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Narrative Update • Dec 23
VIMIAN: Downgrade And New CEO Will Shape Medium Term Risk Outlook
Analysts have lowered their price target on Vimian Group from approximately SEK 37 to around SEK 27. This reflects more cautious assumptions on growth, profitability, and valuation multiples in line with a more conservative sector outlook for 2026.Narrative Update • Dec 09
VIMIAN: Future Leadership Will Drive Cash Flow Execution Upside Despite Sector Downgrade
Analysts have trimmed their price target on Vimian Group by SEK 10 to SEK 27. This reflects slightly higher discount rate assumptions and more conservative long term valuation multiples for the sector.Narrative Update • Nov 25
VIMIAN: Future Leadership and Expanded Acquisitions Will Drive Market Resilience
Narrative Update on Vimian Group Analysts have lowered Vimian Group's fair value estimate from SEK 38.90 to SEK 36.97. This revision is attributed to reduced revenue growth expectations, a higher discount rate, and a more cautious industry outlook reflected in recent research.Analysis Article • Sep 10
Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 40% Above Its Share Price
Key Insights The projected fair value for Vimian Group is kr43.69 based on 2 Stage Free Cash Flow to Equity Vimian...Narrative Update • Sep 05
Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare
Ongoing execution challenges in MedTech, anticipated organic growth slowing to 5% in 2025, and required recovery in orthopedics have led analysts to adopt a more cautious outlook and maintain Vimian Group's price target at SEK38.90. Analyst Commentary Ongoing execution challenges in the MedTech segment are impacting overall group momentum.Analysis Article • Aug 14
Vimian Group AB (publ) (STO:VIMIAN) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
OM:VIMIAN 1 Year Share Price vs Fair Value Explore Vimian Group's Fair Values from the Community and select yours...Analysis Article • Jun 17
If EPS Growth Is Important To You, Vimian Group (STO:VIMIAN) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Jun 02
Estimating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)
Key Insights Vimian Group's estimated fair value is kr55.41 based on 2 Stage Free Cash Flow to Equity Vimian Group's...Analysis Article • May 15
Getting In Cheap On Vimian Group AB (publ) (STO:VIMIAN) Is Unlikely
With a median price-to-sales (or "P/S") ratio of close to 4.6x in the Medical Equipment industry in Sweden, you could...Analysis Article • Mar 05
Is Vimian Group (STO:VIMIAN) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Feb 21
Vimian Group's (STO:VIMIAN) Earnings Are Weaker Than They Seem
Unsurprisingly, Vimian Group AB (publ)'s ( STO:VIMIAN ) stock price was strong on the back of its healthy earnings...Analysis Article • Feb 14
A Look At The Fair Value Of Vimian Group AB (publ) (STO:VIMIAN)
Key Insights The projected fair value for Vimian Group is kr54.92 based on 2 Stage Free Cash Flow to Equity Current...
New Narrative • Feb 09
iM3 Acquisition Will Expand Presence In Veterinary Dental Space
Expansion in Specialty Pharma and strategic focus on cash generation are expected to drive organic growth, enhancing revenue and margins.Analysis Article • Dec 16
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Analysis Article • Aug 31
Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%
Vimian Group AB (publ) ( STO:VIMIAN ) shareholders have had their patience rewarded with a 27% share price jump in the...Analysis Article • Aug 17
Is Vimian Group (STO:VIMIAN) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysis Article • Apr 18
Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Vimian Group AB (publ)'s ( STO:VIMIAN ) robust earnings report didn't manage to move the market for its stock. Our...Analysis Article • Apr 09
Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vimian Group fair value estimate is kr55.14 Vimian Group's...Analysis Article • Feb 13
Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...Analysis Article • Jan 08
Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues
Vimian Group AB (publ)'s ( STO:VIMIAN ) price-to-sales (or "P/S") ratio of 3.6x might make it look like a buy right now...Shareholder Returns
| VIMIAN | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -2.5% | 1.1% | 1.7% |
| 1Y | -28.7% | -8.7% | 12.5% |
Return vs Industry: VIMIAN underperformed the Swedish Medical Equipment industry which returned -8.7% over the past year.
Return vs Market: VIMIAN underperformed the Swedish Market which returned 12.5% over the past year.
Price Volatility
| VIMIAN volatility | |
|---|---|
| VIMIAN Average Weekly Movement | 4.5% |
| Medical Equipment Industry Average Movement | 7.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: VIMIAN has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: VIMIAN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 1,300 | Alireza Tajbakhsh | vimian.com |
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
Vimian Group AB (publ) Fundamentals Summary
| VIMIAN fundamental statistics | |
|---|---|
| Market cap | SEK 15.48b |
| Earnings (TTM) | SEK 407.42m |
| Revenue (TTM) | SEK 4.80b |
38.0x
P/E Ratio3.2x
P/S RatioIs VIMIAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIMIAN income statement (TTM) | |
|---|---|
| Revenue | €433.60m |
| Cost of Revenue | €134.40m |
| Gross Profit | €299.20m |
| Other Expenses | €262.40m |
| Earnings | €36.80m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 17, 2026
| Earnings per share (EPS) | 0.07 |
| Gross Margin | 69.00% |
| Net Profit Margin | 8.49% |
| Debt/Equity Ratio | 31.5% |
How did VIMIAN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/01 23:23 |
| End of Day Share Price | 2026/07/01 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vimian Group AB (publ) is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Jonathon Unwin | Barclays |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |